News Release

 

Back
 

AmerisourceBergen Reports Earnings Per Share Up 48 Percent to $0.86 Before Special Charges in June Quarter

07/31/02

Synergy Capture and Low Interest Expense Continue to Drive Results

VALLEY FORGE, Pa., Jul 31, 2002 (BUSINESS WIRE) -- AmerisourceBergen Corporation (NYSE:ABC) today reported results for its fiscal third quarter and nine months ended June 30, 2002. AmeriSource Health Corporation and Bergen Brunswig Corporation merged on August 29, 2001 to form AmerisourceBergen Corporation. Under purchase accounting rules, AmerisourceBergen's fiscal 2002 third quarter and nine-month results are compared with the fiscal 2001 third quarter and nine-month results of AmeriSource only. Pro forma data included in this discussion refers to the combined predecessor companies' operating results in the previous year's third quarter and first nine months, adjusted to eliminate amortization of goodwill. Both former companies had the same fiscal year ending September 30.

Diluted earnings per share before special charges for the third quarter of fiscal 2002 were $0.86, a 48 percent increase over the previous year's third quarter. Income before special charges for the third quarter of fiscal 2002 increased to $95.1 million from $32.1 million in the same period last year. Special charges, consisting of merger integration costs, were $4.9 million, net of tax, in the quarter. Net income and diluted earnings per share for the quarter were $90.2 million and $0.82, respectively.

AmerisourceBergen's operating revenue, which excludes bulk deliveries to customer warehouses, was $10.3 billion in the third quarter of fiscal 2002 compared to $3.5 billion for the same period last year. Fiscal 2002 third quarter operating revenue increased 14 percent over fiscal 2001 third quarter pro forma operating revenue of $9.0 billion.

For the first nine months of fiscal 2002, diluted earnings per share before special charges were $2.41, a 46 percent increase over the prior year. Special charges, consisting of merger integration costs, were $12.3 million, net of tax, in the first nine months of fiscal 2002. Operating revenue for the nine-month period ended June 30, 2002 was $29.9 billion compared to $10.3 billion in the prior year, and represents a 17 percent increase over pro forma operating revenue of $25.5 billion in the first nine months of fiscal 2001. Net income and diluted earnings per share for the nine-month period ended June 30, 2002 were $250.0 million and $2.30, respectively.

For the third quarter of fiscal 2002, interest expense, including pretax distributions on preferred securities of a subsidiary trust, was $33.3 million, reflecting disciplined asset management and a favorable interest rate environment.

The following discussion of results, including segment data, does not include the impact of the special charges in the third quarter and first nine months of fiscal 2002.

"This was another exceptional performance by AmerisourceBergen, demonstrating our continuing ability to leverage the cost saving and scale synergies of our new company," said R. David Yost, AmerisourceBergen President and Chief Executive Officer. "We continued to capture synergy cost savings from the merger earlier than expected, and new scale synergies are improving contributions from pharmaceutical purchasing. Strong working capital management and a historically low interest rate environment also positively impacted the Company's performance. All these factors drove excellent earnings per share growth, operating margin expansion and a very strong return on committed capital (ROCC) of 24.6 percent.

"During the quarter we announced and this month completed the $120 million acquisition of AutoMed Technologies, Inc. This acquisition, which is expected to be slightly accretive to earnings, enhances our position in the pharmaceutical supply chain by providing our retail and institutional customers with a pharmacy automation solution that reduces the cost of drug dispensing, improves dispensing accuracy and addresses staffing pressures."

    Segment Discussion
AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes the AmerisourceBergen Drug Company and AmerisourceBergen Specialty Group operations) and PharMerica (which includes the institutional pharmacy and workers' compensation fulfillment businesses). Intersegment sales of $189.7 million in the third quarter of fiscal 2002 from AmerisourceBergen Drug Company to PharMerica, which are included in the Pharmaceutical Distribution segment operating revenue, are eliminated for consolidated reporting purposes.

    Pharmaceutical Distribution Segment
Operating revenue in the third quarter of fiscal 2002 increased to $10.1 billion compared with $3.5 billion in the previous year's third quarter. Operating revenue increased 14 percent over fiscal 2001 third quarter pro forma revenue of $8.8 billion.

Pharmaceutical Distribution customer mix in the third quarter of fiscal 2002 was 52 percent institutional and 48 percent retail. AmerisourceBergen is the market leader in pharmaceutical distribution to hospital systems and acute care facilities, alternate care facilities, independent community pharmacies, and regional chain store pharmacies.

Operating income was $169.1 million in the third quarter of fiscal 2002, up from $61.1 million for the same quarter last year, and improved 14 percent compared to pro forma operating income of $147.8 million in the same period last year. For the fiscal 2002 third quarter, operating income, as a percentage of operating revenue, was 1.68 percent, a slight improvement from the prior year's third quarter on a pro forma basis. Lower gross margins, which reflect the Company's customer mix and the competitive environment, were more than offset by lower total operating expenses as a percentage of operating revenue.

Total operating expenses as a percentage of operating revenue in the fiscal 2002 third quarter were 2.15 percent, a 24 basis point improvement over the same quarter last year on a pro forma basis driven by synergy cost savings, customer mix and operating leverage.

AmerisourceBergen Specialty Group, with annualized revenue well over $2.5 billion, had another very strong quarter, building significant positions in oncology, blood plasma and vaccine distribution as well as growing its manufacturing services businesses.

"The momentum from our integration activities continues to build. Distribution center consolidations are on schedule and going smoothly. Last week we successfully completed the consolidation of our Portland, Oregon distribution center into our Seattle facility. Three additional distribution centers are scheduled for consolidation by the end of September, bringing the total number of consolidations in the fiscal year to seven, in line with the goal we set at the beginning of the year," said Kurt J. Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "We also continue to leverage our larger scale as our new generic pharmaceutical program gained traction in the marketplace and our common employee benefits plan was rolled out July 1, 2002. Our recently combined sales force hosted the highly successful first annual AmerisourceBergen Healthcare Conference for customers, establishing the largest such event in the industry with over 6,000 people in attendance."

    PharMerica
PharMerica's operating revenue for the third quarter of fiscal 2002 was $373.8 million, representing an 11 percent increase over pro forma operating revenue of $336.8 million in the same period last year.

Operating income for the third quarter of fiscal 2002 was $21.8 million, a 28 percent increase over the prior year's pro forma third quarter operating income of $17.0 million.

Operating income as a percentage of operating revenue increased 79 basis points in the quarter ended June 30, 2002 to 5.82 percent from 5.03 percent on a pro forma basis in the prior year.

"Double-digit revenue growth reflected continued strong performance by PharMerica's workers compensation business, as well as improved growth in the long-term care business," said Hilzinger. "Cost savings from expense control, driven by the favorable effect of a single information technology platform and continued accounts receivables discipline, as well as the positive impact of the new generic drug program, enhanced PharMerica's performance in the quarter."

    Looking Ahead
"We expect continued strong performance for AmerisourceBergen for the fiscal 2002 fourth quarter with diluted earnings per share excluding special charges in the range of $0.83 to $0.85, ROCC in excess of our 20 percent target, and revenue growth consistent with the third quarter fiscal 2002 performance," said Yost. "We are increasing our diluted earnings per share estimate for fiscal year 2002, excluding the impact of merger-related special charges, from $3.15 to a range of $3.24 to $3.26, the third estimate increase this fiscal year. The increase in earnings expectations for the year reflects the solid performance of our businesses in the third quarter, early capture of cost saving synergies, and continued low interest rates. We remain confident in our ability to achieve annual cost saving synergies of $150 million by the end of fiscal year 2004."

Also, in response to the recent order of the Security and Exchange Commission seeking sworn statements from the principal executive officers and principal financial officers of large public companies, Yost and Senior Vice President and Chief Financial Officer Michael D. DiCandilo each will file certifications by the August 14, 2002 deadline affirming that AmerisourceBergen's 10-K Report for fiscal 2001, 10-Q Reports for fiscal 2002, and 2002 Annual Meeting proxy statement were materially complete and truthful."

    Conference Call
The Company will host a conference call to discuss the results at 11:00 a.m. Eastern Daylight Time on July 31, 2002. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; and Michael D. DiCandilo, Senior Vice President & Chief Financial Officer.

To access the live conference call via telephone:
Dial in:
        800-553-5260 from inside the U.S. no access code required
        or 612-332-1210 from outside the U.S. no access code required.
To access the live webcast:
	   Go to the Quarterly Webcasts section on the Investor Relations
page at http://www.amerisourcebergen.net.
	   A replay of the telephone call and webcast will be available from
4:15 p.m. July 31, 2002 until 11:59 p.m. August 7, 2002.
To access the replay via telephone:
Dial in:
        800-475-6701 from within the U.S., access code: 643950
        320-365-3844 from outside the U.S., access code: 643950
To access the archived webcast:
	   Go to the Quarterly Webcasts section on the Investor Relations
page at http://www.amerisourcebergen.net.
    About AmerisourceBergen
AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems and acute care market, alternate care facilities, independent community pharmacies, and regional chain pharmacies. The Company is also a leader in the institutional pharmacy marketplace. With more than $40 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

    Forward-Looking Statements
This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001, its Quarterly Reports on Form 10-Q for the first and second quarters of fiscal 2002, and the joint proxy statement-prospectus for the merger as filed on August 1, 2001.

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward-looking statements whether as a result of new information, future events or otherwise.

                     AMERISOURCEBERGEN CORPORATION
                           FINANCIAL SUMMARY
                 (In thousands, except per share data)
                              (unaudited)
                     Three                 Three
                     Months                Months
                     Ended       % of      Ended      % of
                    June 30,   Operating  June 30,  Operating    %
                      2002      Revenue     2001     Revenue   Change
                   -----------  -------  ----------- -------  -------
Revenue:
 Operating revenue $10,278,327   100.00% $3,518,852   100.00%     192%
 Bulk deliveries
  to customer
  warehouses         1,342,500                    77               --
                   -----------           -----------
Total revenue       11,620,827             3,518,929              230%
Cost of goods sold  11,110,898             3,373,990              229%
                   -----------           -----------
Gross profit           509,929     4.96%     144,939    4.12%     252%
Operating expenses:
 Distribution,
  selling and
  administrative       304,299     2.96%      79,638    2.26%     282%
 Depreciation and
  amortization          14,740     0.14%       4,205    0.12%     251%
 Merger costs            8,147     0.08%         903    0.03%      --
                   -----------           -----------
Operating income       182,743     1.78%      60,193    1.71%     204%
Equity in (income)
 losses of
 affiliates and
 other                    (190)    0.00%      2,006     0.06%    -109%
Interest expense        27,308     0.27%       7,361    0.21%     271%
                   -----------           -----------
Income before taxes
 and distributions
 on preferred
 securities of
 subsidiary trust      155,625     1.51%      50,826    1.44%     206%
Income taxes            61,771     0.60%      19,320    0.55%     220%
                   -----------           -----------
Income before
 distributions on
 preferred
 securities
 of subsidiary
 trust                  93,854     0.91%      31,506    0.90%     198%
Distributions on
 preferred
 securities of
 subsidiary
 trust, net of
 income tax
 benefit of
 $2,388                  3,630     0.04%          --    0.00%      --
                   -----------           -----------
Net income         $    90,224     0.88% $    31,506    0.90%     186%
                   ===========           ===========
Earnings per share:
 Basic             $      0.86           $      0.60
 Diluted           $      0.82           $      0.57
Weighted average
common shares
outstanding:
 Basic                 105,374                52,912
 Diluted               112,891                59,578
----------------------------------------------------------------------
Pro forma results excluding merger costs in the three months ended
June 30, 2002 and 2001:
Operating income   $   190,890           $    61,096
Net income         $    95,136           $    32,066
Earnings per share:
 Basic             $      0.90           $      0.61
 Diluted           $      0.86           $      0.58
                     AMERISOURCEBERGEN CORPORATION
                           FINANCIAL SUMMARY
                 (In thousands, except per share data)
                              (unaudited)
                      Nine                 Nine
                     Months               Months
                     Ended       % of      Ended      % of
                    June 30    Operating  June 30   Operating    %
                     2002       Revenue     2001     Revenue  Change
                   -----------  -------  ----------- -------  -------
Revenue:
 Operating revenue $29,883,212   100.00% $10,306,288  100.00%     190%
 Bulk deliveries
  to customer
  warehouses         3,750,662                   834               --
                   -----------           -----------
Total revenue       33,633,874            10,307,122              226%
Cost of goods
 sold               32,138,019             9,873,581              225%
                   -----------           -----------
Gross profit         1,495,855     5.01%     433,541    4.21%     245%
Operating expenses:
 Distribution,
  selling and
  administrative       906,467     3.03%     241,745    2.35%     275%
 Depreciation and
  amortization          44,189     0.15%      12,380    0.12%     257%
 Merger costs           20,385     0.07%         903    0.01%      --
                   -----------           -----------
Operating income       524,814     1.76%     178,513    1.73%     194%
Equity in losses
 of affiliates
 and other               1,187     0.00%       4,581    0.04%     -74%
Interest expense        91,017     0.30%      30,030    0.29%     203%
                   -----------           -----------
Income before
 taxes and
 distributions on
 preferred
 securities of
 subsidiary trust      432,610     1.45%     143,902    1.40%     201%
Income taxes           171,740     0.57%      54,689    0.53%     214%
                   -----------           -----------
Income before
 distributions on
 preferred
 securities
 of subsidiary
 trust                 260,870     0.87%      89,213    0.87%     192%
Distributions on
 preferred
 securities of
 subsidiary
 trust, net of
 income tax
 benefit
 of $7,165              10,889     0.04%          --    0.00%      --
                   -----------           -----------
Net income         $   249,981     0.84% $    89,213    0.87%     180%
                   ===========           ===========
Earnings per share:
 Basic             $      2.39           $      1.69
 Diluted           $      2.30           $      1.64
Weighted average
common shares
outstanding:
 Basic                 104,505                52,656
 Diluted               111,926                57,819
----------------------------------------------------------------------
Pro forma results excluding merger costs in the nine months ended
June 30, 2002 and 2001:
Operating income   $   545,199           $   179,416
Net income         $   262,273           $    89,773
Earnings per share:
 Basic             $      2.51           $      1.70
 Diluted           $      2.41           $      1.65
                     AMERISOURCEBERGEN CORPORATION
                 CONDENSED CONSOLIDATED BALANCE SHEETS
                        (dollars in thousands)
            ASSETS          (Unaudited)
                              June 30      September 30,        $
                               2002            2001           Change
                            -----------    -----------    -----------
Current assets:
   Cash and cash
    equivalents             $   363,406    $   297,626    $    65,780
   Accounts
    receivable,
    net                       2,131,273      2,142,663        (11,390)
   Merchandise
    inventories               5,174,024      5,056,257        117,767
   Prepaid
    expenses and
    other                        18,793         15,956          2,837
                            -----------    -----------    -----------
     Total
      current
      assets                  7,687,496      7,512,502        174,994
Long-term assets              2,745,198      2,778,743        (33,545)
                            -----------    -----------    -----------
     Total
      assets                $10,432,694    $10,291,245    $   141,449
                            ===========    ===========    ===========
            LIABILITIES AND STOCKHOLDERS' EQUITY
Current
 liabilities:
  Accounts
   payable                  $ 4,764,316    $ 4,991,884    ($  227,568)
  Current
   portion of
   long-term debt                45,000          2,468         42,532
  Other current
   liabilities                  633,998        538,101         95,897
                            -----------    -----------    -----------
    Total current
     liabilities              5,443,314      5,532,453        (89,139)
Long-term debt,
 less current
 portion                      1,493,511      1,597,295       (103,784)
Other liabilities                30,678         48,317        (17,639)
Company-obligated
 mandatorily
 redeemable
 preferred
 securities of
 subsidiary trust               275,120        274,616            504
Stockholders'
 equity                       3,190,071      2,838,564        351,507
                            -----------    -----------    -----------
    Total
     liabilities
     and
     stockholders'
     equity                 $10,432,694    $10,291,245    $   141,449
                            ===========    ===========    ===========
                     AMERISOURCEBERGEN CORPORATION
                      SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                               Three Months Ended June 30,
               -------------------------------------------------------
                  Actual        Actual       Pro forma Actual %  Pro
Operating          2002          2001         2001 (1)  Change forma %
   Revenue                                                     Change
 ------------- -------------------------------------------------------
Pharmaceutical
 Distribution  $10,094,205    $3,518,852    $8,835,163    187%    14%
PharMerica         373,791          --         336,783     --     11%
Intersegment
 Eliminations     (189,669)         --        (176,831)    --      7%
               ------------   -----------   ----------- ------ ------
  Operating
   revenue     $10,278,327    $3,518,852    $8,995,115    192%    14%
               ============   ===========   =========== ====== ======
                           Three Months Ended June 30,
               -------------------------------------------------------
Operating          Actual        Actual     Pro forma  Actual %  Pro
   Income (2)       2002          2001       2001 (1)   Change forma %
                                                                Change
 ------------- -------------------------------------------------------
Pharmaceutical
 Distribution     $169,134       $61,096      $147,826    177%    14%
PharMerica          21,756          --          16,956    --      28%
               ------------   -----------   ----------- ------ ------
  Operating
   income         $190,890       $61,096      $164,782    212%    16%
               ============   ===========   =========== ====== ======
Percentages of
 operating revenue (2):
Pharmaceutical
 Distribution
  Gross profit        3.83%         4.12%         4.06%
  Operating
   expenses           2.15%         2.38%         2.39%
  Operating
   income             1.68%         1.74%         1.67%
PharMerica
  Gross profit       33.11%           --         34.80%
  Operating
   expenses          27.29%           --         29.76%
  Operating
   income             5.82%           --          5.03%
AmerisourceBergen
 Corporation
  Gross profit        4.96%         4.12%         5.29%
  Operating
   expenses           3.10%         2.38%         3.46%
  Operating
   income             1.86%         1.74%         1.83%
(1)   Represents the combination of AmeriSource Health Corporation's
      and Bergen Brunswig Corporation's previously reported financial
      information. (See discussion under Pro Forma Information
      Appendix - A(1)).
(2)   Excludes merger costs.
                     AMERISOURCEBERGEN CORPORATION
                      SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                             Nine Months Ended June 30,
               -----------------------------------------------------
                                                               Pro
Operating         Actual       Actual    Pro forma   Actual % forma %
 Revenue           2002         2001      2001 (1)    Change  Change
-------------- -----------------------------------------------------
Pharmaceutical
 Distribution  $29,367,184  $10,306,288  $25,100,466    185%    17%
PharMerica       1,088,967           --    1,011,873      --     8%
Intersegment
 Eliminations     (572,939)          --     (565,713)     --     1%
               ------------ ------------ ------------ --------------
    Operating
     revenue   $29,883,212  $10,306,288  $25,546,626    190%    17%
               ============ ============ ============ ==============
                            Nine Months Ended June 30,
                -------------------------------------------------
Operating        Actual    Actual   Pro forma  Actual %  Pro forma %
 Income (2)       2002      2001     2001 (1)   Change     Change
--------------- -------------------------------------------------
Pharmaceutical
 Distribution   $484,586  $179,416   $408,630    170%        19%
PharMerica        60,613        --     50,177      --        21%
                --------- --------- ---------- ------------------
    Operating
     income     $545,199  $179,416   $458,807    204%        19%
                ========= ========= ========== ==================
Percentages of operating revenue (2):
Pharmaceutical
 Distribution
  Gross profit      3.85%     4.21%      4.14%
  Operating
   expenses         2.20%     2.47%      2.51%
  Operating
   income           1.65%     1.74%      1.63%
PharMerica
  Gross profit     33.41%        --     35.49%
  Operating
   expenses        27.85%        --     30.53%
  Operating
   income           5.57%        --      4.96%
AmerisourceBergen
 Corporation
  Gross profit      5.01%     4.21%      5.47%
  Operating
   expenses         3.18%     2.47%      3.68%
  Operating
   income           1.82%     1.74%      1.80%
(1)    Represents the combination of AmeriSource Health Corporation's
       and Bergen Brunswig Corporation's previously reported financial
       information. (See discussion under Pro Forma Information
       Appendix - A(1)).
(2)    Excludes merger costs.
                         AMERISOURCEBERGEN CORPORATION
                              EARNINGS PER SHARE
                    (In thousands, except per share data)
                                 (unaudited)
	   Basic earnings per share is computed on the basis of the weighted
average number of shares of common stock outstanding during the
periods presented. Diluted earnings per share is computed on the basis
of the weighted average number of shares of common stock outstanding
during the period plus the dilutive effect of stock options.
Additionally, the diluted earnings per share calculation considers the
convertible subordinated notes as if converted and, therefore, the
effect of interest expense related to those notes is added back to net
income in determining income available to common stockholders.
                             Three months ended     Nine months ended
                                  June 30,               June 30,
                               2002      2001        2002       2001
                             -------   -------      -------   -------
Net income                   $90,224   $31,506     $249,981   $89,213
Interest expense -
 convertible
 subordinated notes,
 net of income taxes           2,481     2,513        7,442     5,599
                             -------   -------      -------   -------
Income available to
 common stockholders         $92,705   $34,019     $257,423   $94,812
                             =======   =======      =======   =======
Weighted average
 common shares
 outstanding                 105,374    52,912      104,505    52,656
Effect of dilutive
 securities:
   Options to
    purchase common
    stock                      1,853     1,002        1,757       993
   Convertible
    subordinated
    notes                      5,664     5,664        5,664     4,170
                             -------   -------      -------   -------
Weighted average
 common shares
 outstanding -
 diluted                     112,891    59,578      111,926    57,819
                             =======   =======      =======   =======
Earnings per share:
       Basic                   $0.86     $0.60        $2.39     $1.69
       Diluted                 $0.82     $0.57        $2.30     $1.64
Appendix - A(1)
Pro Forma Information
	   The historical consolidated financial summary and summary segment
information for the three-months and nine-months ended June 30, 2001,
included in this press release, reflect only the results of
AmeriSource Health Corporation, as predecessor to the Company. In
order to enhance comparability, the following schedules as well as the
summary segment information include fiscal 2001 financial data on a
pro forma basis. Within these schedules, pro forma refers to the
combined results of AmeriSource Health Corporation and Bergen Brunswig
Corporation and are not intended to be consolidated financial
statements of AmerisourceBergen prepared in accordance with generally
accepted accounting principles and do not represent consolidated
results as if the merger had occurred at the beginning of the periods
presented. In addition, they are not necessarily indicative of the
actual results which might have occurred had the operations and
management of AmeriSource Health Corporation and Bergen Brunswig
Corporation been combined at the beginning of fiscal 2001.
	   In addition, to enhance comparability of financial information
between fiscal years, the pro forma information for fiscal 2001
excludes the amortization of goodwill and special items related to the
merger and environmental remediation and reflects the full allocation
of Bergen Brunswig Corporation's former Corporate segment to the
Pharmaceutical Distribution and PharMerica segments.
Appendix - A(2)
AmerisourceBergen
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                       Fiscal Year Ended September 30, 2001
            ----------------------------------------------------------
              First      Second       Third      Fourth      Fiscal
             Quarter     Quarter     Quarter     Quarter      Year
----------------------------------------------------------------------
Operating
 revenue   $8,083,535  $8,467,976  $8,995,115  $9,052,684  $34,599,310
            ==========================================================
Gross
 profit      $442,249    $480,035    $475,810    $482,647   $1,880,741
Distribution,
 selling and
 administrative
 (2)          293,608     303,730     295,462     304,703    1,197,503
Depreciation   13,891      14,337      14,296      14,641       57,165
Amortization
 (3)            1,553       1,140       1,270       1,427        5,390
             ---------------------------------------------------------
Operating
 income      $133,197    $160,828    $164,782    $161,876     $620,683
             =========================================================
Gross profit
 to operating
 revenue        5.47%       5.67%       5.29%       5.33%        5.44%
Operating
 expenses to
 operating
 revenue        3.82%       3.77%       3.46%       3.54%        3.64%
Operating
 income
 to operating
 revenue        1.65%       1.90%       1.83%       1.79%        1.79%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the third and fourth quarters related to
    the merger and enviromental remediation.
(3) Excludes amortization of goodwill.
Appendix - A(3)
AmerisourceBergen - Pharmaceutical Distribution
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                         Fiscal Year Ended September 30, 2001
              --------------------------------------------------------
                 First     Second      Third     Fourth   Fiscal Year
                Quarter    Quarter    Quarter    Quarter
----------------------------------------------------------------------
Operating
 revenue      $7,929,966 $8,335,337 $8,835,163 $8,885,145 $33,985,611
              ========================================================
Gross profit    $322,096   $358,294   $358,619   $365,948  $1,404,957
Distribution,
 selling and
 administrative
 (2), (3)        195,464    202,915    200,042    211,501     809,922
Depreciation       9,426      9,962      9,916     10,278      39,582
Amortization (4)   1,116        703        835        972       3,626
              --------------------------------------------------------
Operating
 income         $116,090   $144,714   $147,826   $143,197    $551,827
              ========================================================
Gross profit to
 operating
 revenue            4.06%      4.30%      4.06%      4.12%       4.13%
Operating
 expenses to
 operating
 revenue            2.60%      2.56%      2.39%      2.51%       2.51%
Operating
 income to
 operating
 revenue            1.46%      1.74%      1.67%      1.61%       1.62%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the third and fourth quarters related to
    the merger and enviromental remediation.
(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.
(4) Excludes amortization of goodwill.
Appendix - A(4)
AmerisourceBergen - PharMerica
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                         Fiscal Year Ended September 30, 2001
              --------------------------------------------------------
                 First     Second      Third     Fourth   Fiscal Year
                Quarter    Quarter    Quarter    Quarter
----------------------------------------------------------------------
Operating
 revenue        $335,166   $339,924   $336,783   $338,135  $1,350,008
              ========================================================
Gross profit    $120,153   $121,741   $117,191   $116,699    $475,784
Distribution,
 selling and
 administrative
 (2), (3)         98,144    100,815     95,420     93,202     387,581
Depreciation       4,465      4,375      4,380      4,363      17,583
Amortization (4)     437        437        435        455       1,764
              --------------------------------------------------------
Operating
 income          $17,107    $16,114    $16,956    $18,679     $68,856
              ========================================================
Gross profit
 to operating
 revenue           35.85%     35.81%     34.80%     34.51%      35.24%
Operating
 expenses to
 operating
 revenue           30.74%     31.07%     29.76%     28.99%      30.14%
Operating
 income to
 operating
 revenue            5.10%      4.74%      5.03%      5.52%       5.10%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the third and fourth quarters related to
    the merger and enviromental remediation.
(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.
(4) Excludes amortization of goodwill.
Appendix - A(5)
AmerisourceBergen - Intersegment Eliminations
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                         Fiscal Year Ended September 30, 2001
              --------------------------------------------------------
                 First     Second      Third     Fourth   Fiscal Year
                Quarter    Quarter    Quarter    Quarter
----------------------------------------------------------------------
Operating
 revenue       ($181,597) ($207,285) ($176,831) ($170,596)  ($736,309)
              ========================================================
Gross profit          $0         $0         $0         $0          $0
Distribution,
 selling and
 administrative       --         --         --         --          --
Depreciation          --         --         --         --          --
Amortization          --         --         --         --          --
              --------------------------------------------------------
Operating
 income               $0         $0         $0         $0          $0
              ========================================================
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
CONTACT:          AmerisourceBergen
                  Michael N. Kilpatric, 610/727-7118
                  mkilpatric@amerisource.com

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More